Protein phosphatase inhibitors

• US 20080051464A1
• Filed: 06/28/2007
• Published: 02/28/2008
• Est. Priority Date: 06/28/2006
• Status: Abandoned Application

• Current Assignee: Cleveland Clinic Foundation
• Original Assignee: Cleveland Clinic Foundation
• Inventors: Yi, Taolin
• Application Number:
  US11/823,505
• Publication Number:
  US 20080051464A1
• Time in Patent Office: Days
• US Class Current: 514/681
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method of inhibiting protein tyrosine phosphatase in a subject includes administering to the subject a therapeutically effective amount of at least one benzo-1,4-quinone, phenyl isothiazolone, or analog thereof to the subject.

Claims

1. A method of inhibiting protein tyrosine phosphatase in a subject, the method comprising:

administering to the subject a therapeutically effective amount of at least one benzo-1,4-quinone or analog thereof.

2. The method of claim 1, the benzo-1,4-quinone or analog thereof comprising the formula (I):

3. The method of claim 1, the benzo-1,4-quinone or analog thereof being administered at an amount effective to inhibit SHP-1 in the subject.

4. The method of claim 1, the benzo-1,4-quinone or analog thereof being administered at an amount effective to inhibit neoplastic cell growth in the subject.

5. The method of claim 1, the benzo-1,4,-quinone or analog thereof being administered at an amount effective to induce immune cells activation in a subject.

6. The method of claim 1, the benzo-1,4-quinone or analog thereof being administered at an amount effective to induce a cytokine responses in the subject.

7. The method of claim 1, the benzo-1,4-quinone or analog thereof being administered at about 1 μ

g/kg to about 10 mg/kg to the subject.

8. The method of claim 1, the benzo-1,4-quinone or analog thereof comprising at least one of the following formulas:

9. The method of claim 1, the benzo-1,4-quinone comprising at least one of the following formulas:

10. A method of treating a neoplastic disorder or proliferative disorder in a subject, the method comprising:

administering to the subject an amount of at least one benzo-1,4-quinone or analog thereof to the subject effective to inhibit neoplastic cell growth in the subject.

11. The method of claim 10, the benzo-1,4-quinone or analogs thereof comprising the formula (I):

12. The method of claim 10, the benzo-1,4-quinone or analog thereof being administered at an amount effective to inhibit SHP-1 in the subject.

13. The method of claim 10, the benzo-1,4,-quinone or analog thereof being administered at an amount effective to induce immune cells activation in a subject.

14. The method of claim 10, the benzo-1,4-quinone or analog thereof being administered at an amount effective to induce a cytokine responses in the subject.

15. The method of claim 10, the neoplastic cell comprising at least one of a cancer cell or tumor cell.

16. The method of claim 10, the benzo-1,4-quinone or analog thereof being administered at about 1 μ

g/kg to about 10 mg/kg to the subject.

17. The method of claim 10, the benzo-1,4-quinone or analog thereof comprising at least one of the following formulas:

18. The method of claim 10, the benzo-1,4-quinone comprising at least one of the following formulas:

19. A method of inducing immune cell activation in a subject being treated, the method comprising:

administering to the subject an amount of at least one benzo-1,4-quinone or analog thereof to the subject effective to induce immune cell activation.

20. The method of claim 19, the benzo-1,4-quinone or analog thereof comprising the formula (I):

21. The method of claim 19, the benzo-1,4-quinone or analog thereof being administered at an amount effective to inhibit SHP-1 in the subject.

22. The method of claim 19, the immune cell comprising IFNγ

+ cells.

23. The method of claim 19, the benzo-1,4-quinone or analog thereof being administered at an amount effective to induce a cytokine responses in the subject.

24. The method of claim 19, the benzo-1,4-quinone or analog thereof being administered at about 1 μ

g/kg to about 10 mg/kg to the subject.

25. The method of claim 19, the benzo-1,4-quinone or analog thereof comprising at least one of the following formulas:

26. The method of claim 19, the benzo-1,4-quinone comprising at least one of the following formulas: